Nasdaq News

Global integrated energy giant ExxonMobil (NYSE: XOM) is investing heavily in new oil production. That's going against the grain today with low oil prices and Wall Street increasingly pushing oil companies to pull back on their spending plans. The thing is, Exxon thinks it has s

It has been about a month since the last earnings report for Danaher (DHR). Shares have lost about 14.5% in that time frame, underperforming the S&P 500.

It has been about a month since the last earnings report for Amazon (AMZN). Shares have added about 0.7% in that time frame, outperforming the S&P 500.

A month has gone by since the last earnings report for Eastman Chemical (EMN). Shares have lost about 11.6% in that time frame, underperforming the S&P 500.

It has been about a month since the last earnings report for Carpenter Technology (CRS). Shares have lost about 13.1% in that time frame, underperforming the S&P 500.

A month has gone by since the last earnings report for Sherwin-Williams (SHW). Shares have lost about 9.2% in that time frame, outperforming the S&P 500.

It has been about a month since the last earnings report for Spectrum Brands (SPB). Shares have lost about 11% in that time frame, underperforming the S&P 500.

The following are today's upgrades for Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.

The following are today's upgrades for Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.

The following are today's upgrades for Validea's Growth/Value Investor model based on the published strategy of James P. O'Shaughnessy. This two strategy approach offers a large-cap value model and a growth approach that looks for persistent earnings growth and strong relative

The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.

The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.

The following are today's upgrades for Validea's Book/Market Investor model based on the published strategy of Joseph Piotroski. This value-quant strategy screens for high book-to-market stocks, and then separates out financially sound firms by looking at a host of improving f

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.

The following are today's upgrades for Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.

The following are today's upgrades for Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.

The following are today's upgrades for Validea's Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.

Vir Biotechnology (NASDAQ: VIR) may not be a familiar name to many investors. This relatively young biotech went public last October. Backed by infamous investor SoftBank (of WeWork fame) among others, investors in Vir find themselves in a situation where they truly are betting

I'm a big believer in "skin in the game." If someone -- like me -- is going to write about how a stock is a great buy, I think they'd better back that up with their own money. Otherwise, if the stock tanks, the writer still gets paid while everyone who took that advice loses mon